BioPharmSignal logoBioPharmSignal

Biotech News

MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes

MannKind (MNKD)MannKindFDA / regulatory

Enables dosing at the start of a meal, offering flexibility for children and adolescents as they manage school, sports, meals, and snacks throughout the day Approval advances pediatric diabetes care by introducing a new inhaled mealtime insulin option recognized in the American Diabetes Association

Related news

MNKDMannKind2026-07-24 10:30 EST

MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease

MNKDMannKind2026-06-05 23:35 EST

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems

RYTMRhythm Pharmaceuticals2026-09-22 12:00 EST

Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity

MISTMilestone Pharmaceuticals Inc.2026-09-03 13:35 EST

Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States

VANIVivani Medical2026-06-25 11:30 EST

Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management

NAMSNewAmsterdam Pharma2026-09-21 13:00 EST

NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)

RYTMRhythm Pharmaceuticals2026-08-24 12:00 EST

Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan

SGMTSagimet Biosciences2026-08-13 11:00 EST

Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients

VKTXViking Therapeutics2026-06-11 11:05 EST

Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer

LXRXLexicon Pharmaceuticals2026-06-03 12:00 EST

Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions

View all latest news

MannKind

Inhaled Drug Delivery MannKind develops and commercializes drug-device combinations using Technosphere particles and dry-powder inhalers for rapid, deep-lung delivery. Commercial Portfolio Afrezza is an inhaled mealtime insulin, Tyvaso DPI is manufactured for United Therapeutics, and FUROSCIX provides subcutaneous furosemide for fluid...

Recent company news

MNKDMannKind2026-09-09 10:30 EST

MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management

MNKDMannKind2026-09-09 10:30 EST

MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management

MNKDMannKind2026-09-02 12:30 EST

MannKind to Present at Upcoming Investor Conferences

MNKDMannKind2026-09-02 12:30 EST

MannKind to Present at Upcoming Investor Conferences

MNKDMannKind2026-08-05 20:01 EST

MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update

Stock data

Close
3.95 USD
Market cap
1.06B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States